Earnings Call Summary | Eastman Kodak(KODK.US) Q2 2024 Earnings Conference
Earnings Call Summary | Eastman Kodak(KODK.US) Q2 2024 Earnings Conference
Kodak experienced an 8% decrease in gross profit compared to the prior year, totaling a $5 million drop, mainly due to higher material and operating costs.The following is a summary of the Eastman Kodak Company (KODK) Q2 2024 Earnings Call Transcript:
以下是柯達公司（KODK）2024年Q2業績會簡報摘要：
Financial Performance:
金融業績：
For Q2 2024, Kodak reported a revenue of $267 million, a 9% decline year-over-year, adjusted for foreign exchange impact it's an 8% decrease.
The gross profit percentage for Q2 increased to 22% from 21% in the previous year.
Kodak experienced an 8% decrease in gross profit compared to the prior year, totaling a $5 million drop, mainly due to higher material and operating costs.
Net income for Q2 2024 was $26 million, a $9 million decrease from the prior year's $35 million.
Operational EBITDA witnessed a decline of $10 million from the previous year, settling at $12 million for Q2.
在2024年Q2，柯達報告收入爲2.67億美元，同比下降9％，調整爲匯率期貨後下降了8％。
2024年Q2毛利潤率從前一年的21%增加到22%。
與前一年相比，柯達的毛利潤下降了8％，總計500萬美元，主要是由於較高的材料和運營成本。
2024年Q2的淨利潤爲2600萬美元，比去年同期的3500萬美元下降了900萬美元。
2024年Q2運營EBITDA與去年相比下降了1000萬美元，降至1200萬美元。
Business Progress:
業務進展：
Kodak is heavily investing in Advanced Materials & Chemicals (AMC), focusing on growth in this key area with upcoming projects like the cGMP facility for diagnostic test reagents.
Continued investment in film manufacturing capacity to cater to increasing demand highlighted by recent successful film projects.
Innovations in the print sector showcased at drupa 2024 with new products such as PROSPER ULTRA 520, enhanced PRINERGY software, and SONORA XTRA next-generation plates.
柯達正在大力投資於化學品和高級材料（AMC），專注於這一重要領域的增長，即將推出類GMP診斷試劑試劑的工廠等項目。
繼最近成功的電影項目後，繼續投資於膠片製造產能以迎接不斷增長的需求。
在2024年的drupa展會上展示了印刷領域的創新產品，例如PROSPER ULTRA 520、增強版PRINERGY軟件和SONORA XTRA下一代版式。
Opportunities:
機會：
The setup of the cGMP facility for diagnostic test reagents represents a significant growth opportunity in the biotechnology sector, scheduled to start production in 2025.
建立診斷試劑試劑類GMP工廠代表生物技術領域的重大增長機會，計劃於2025年開始生產。
Risks:
風險：
A deliberate revenue decrease in line with refining customer base and product suite, focusing on 'smart revenue', might risk near-term revenue dips but aims for long-term gain.
遵循精細化客戶群和產品組合的「智能收入」戰略，有意減少收入，可能會冒風險，但旨在實現長期收益。
More details: Eastman Kodak IR
更多詳情：柯達IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
